Background
Adapt Pharma holds the patents covering NARCAN® Nasal Spray, a life-saving opioid overdose reversal product that delivers naloxone intranasally without needles. Naloxone — an opioid receptor antagonist that rapidly reverses opioid overdose — had been known for decades, but getting a reliable, sufficient dose of it through the nasal passage was challenging. Adapt’s patents claim specific formulations and methods for intranasal naloxone delivery in concentrations sufficient to reverse overdose.
As part of a Hatch-Waxman (generic drug) challenge, Teva sought to market a generic naloxone nasal spray and filed an ANDA, certifying that the Adapt patents were invalid. The district court agreed, finding the asserted claims obvious in light of prior art including earlier intranasal naloxone formulations and a 2012 FDA call-to-action encouraging development of an approved intranasal naloxone product. Adapt appealed, arguing the prior art lacked the specific combination claimed and that extensive secondary considerations — including commercial success, long-felt need, failure of others, and skepticism — demonstrated nonobviousness.
The Court’s Holding
The Federal Circuit affirmed, with a majority of Judges Lourie and Chen holding that the district court’s obviousness findings were not clearly erroneous.
On motivation to combine, the majority found substantial evidence that a skilled artisan would have been motivated to develop an FDA-approvable intranasal naloxone product by the mid-2010s: existing formulations had known shortcomings in bioavailability and dosing consistency, the FDA had publicly identified this as a priority, and the prior art provided documented starting points for formulating intranasal naloxone. The court found that the combination of the prior art references would have suggested the claimed approach, and that the expectation of success was reasonable.
On secondary considerations, the court was not persuaded that Adapt’s evidence was sufficient to overcome the strong case for obviousness. The FDA’s open call for an approved product — which Adapt had cited as evidence of long-felt need — cut both ways: it also showed that the agency and scientific community believed the product was achievable, undermining any inference that the problem was considered unsolved or unsolvable.
Judge Newman dissented sharply, arguing that the prior art did not teach the specific combination of ingredients and concentrations claimed in Adapt’s patents, and that the majority improperly used hindsight to reconstruct the invention from the prior art. Newman would have reversed the invalidity finding.
Key Takeaways
- A regulatory call-to-action (such as an FDA request for improved formulations) may simultaneously serve as evidence of long-felt need and as evidence that skilled artisans believed the problem was solvable — weakening its effectiveness as a secondary consideration of nonobviousness.
- Commercial success of life-saving drug products is not sufficient on its own to overcome strong evidence of motivation to combine where the prior art identified the same problem and suggested related solutions.
- Hatch-Waxman pharmaceutical patent challenges routinely involve obviousness disputes over formulation patents, and this case illustrates the difficulty of maintaining patent protection when prior art is rich in related formulations and the problem the inventor solved was publicly identified.
- The dissent underscores the enduring tension in obviousness doctrine between proper hindsight analysis and the legitimate use of background knowledge to evaluate what a skilled artisan would have done.
Why It Matters
The case has significant public health and commercial implications. NARCAN Nasal Spray became one of the most important tools in combating the opioid epidemic — widely distributed to first responders, pharmacies, and community organizations. The Federal Circuit’s ruling allowed generic manufacturers to enter the market sooner, which could reduce costs and expand access to the overdose reversal medication.
For pharmaceutical patent holders, the case reinforces the risk of obviousness challenges to formulation patents where prior art is dense and the FDA has publicly identified the clinical need. The decision also adds to the body of law on secondary considerations, illustrating that even strong commercial success and public health urgency may not overcome clear evidence of motivation to combine when multiple prior art references point in the same direction.